187 related articles for article (PubMed ID: 25491250)
1. Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer.
van der Mijn JC; Sol N; Mellema W; Jimenez CR; Piersma SR; Dekker H; Schutte LM; Smit EF; Broxterman HJ; Skog J; Tannous BA; Wurdinger T; Verheul HM
J Extracell Vesicles; 2014; 3():25657. PubMed ID: 25491250
[TBL] [Abstract][Full Text] [Related]
2. Large and small extracellular vesicles released by glioma cells
Yekula A; Minciacchi VR; Morello M; Shao H; Park Y; Zhang X; Muralidharan K; Freeman MR; Weissleder R; Lee H; Carter B; Breakefield XO; Di Vizio D; Balaj L
J Extracell Vesicles; 2020; 9(1):1689784. PubMed ID: 31839905
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of phosphoproteomics to uncover oncogenic signalling in secreted extracellular vesicles using glioblastoma-EGFRVIII cells as a model.
Bijnsdorp IV; Schelfhorst T; Luinenburg M; Rolfs F; Piersma SR; de Haas RR; Pham TV; Jimenez CR
J Proteomics; 2021 Feb; 232():104076. PubMed ID: 33307249
[TBL] [Abstract][Full Text] [Related]
4. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.
Montermini L; Meehan B; Garnier D; Lee WJ; Lee TH; Guha A; Al-Nedawi K; Rak J
J Biol Chem; 2015 Oct; 290(40):24534-46. PubMed ID: 26272609
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
12. Escherichia coli-derived and Staphylococcus aureus-derived extracellular vesicles induce MUC5AC expression via extracellular signal related kinase 1/2 and p38 mitogen-activated protein kinase in human airway epithelial cells.
Bae CH; Choi YS; Song SY; Kim YK; Kim YD
Int Forum Allergy Rhinol; 2017 Jan; 7(1):91-98. PubMed ID: 27595564
[TBL] [Abstract][Full Text] [Related]
13. Alpha 2-Adrenergic Receptor Agonist Brimonidine Stimulates ERK1/2 and AKT Signaling via Transactivation of EGF Receptors in the Human MIO-M1 Müller Cell Line.
Harun-Or-Rashid M; Hallböök F
Curr Eye Res; 2019 Jan; 44(1):34-45. PubMed ID: 30198788
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
15. Smoking Induced Extracellular Vesicles Release and Their Distinct Properties in Non-Small Cell Lung Cancer.
Wu F; Yin Z; Yang L; Fan J; Xu J; Jin Y; Yu J; Zhang D; Yang G
J Cancer; 2019; 10(15):3435-3443. PubMed ID: 31293647
[No Abstract] [Full Text] [Related]
16. Indoxyl Sulfate-Induced Extracellular Vesicles Released from Endothelial Cells Stimulate Vascular Smooth Muscle Cell Proliferation by Inducing Transforming Growth Factor-Beta Production.
Ryu JH; Jeon EY; Kim SJ
J Vasc Res; 2019; 56(3):129-138. PubMed ID: 31085925
[TBL] [Abstract][Full Text] [Related]
17. H2O2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells.
Zhuang S; Schnellmann RG
Am J Physiol Renal Physiol; 2004 May; 286(5):F858-65. PubMed ID: 15075181
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab treatment alters the content of extracellular vesicles released from tumor cells.
van Dommelen SM; van der Meel R; van Solinge WW; Coimbra M; Vader P; Schiffelers RM
Nanomedicine (Lond); 2016 Apr; 11(8):881-90. PubMed ID: 27021928
[TBL] [Abstract][Full Text] [Related]
19. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles.
Zanetti-Domingues LC; Bonner SE; Martin-Fernandez ML; Huber V
Cells; 2020 Nov; 9(11):. PubMed ID: 33228060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
